Last reviewed · How we verify
Evobrutinib MR-T3
Evobrutinib MR-T3 is a Small molecule drug developed by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. It is currently in Phase 1 development. Also known as: M2951.
At a glance
| Generic name | Evobrutinib MR-T3 |
|---|---|
| Also known as | M2951 |
| Sponsor | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Evobrutinib MR-T3 CI brief — competitive landscape report
- Evobrutinib MR-T3 updates RSS · CI watch RSS
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany portfolio CI
Frequently asked questions about Evobrutinib MR-T3
What is Evobrutinib MR-T3?
Evobrutinib MR-T3 is a Small molecule drug developed by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany.
Who makes Evobrutinib MR-T3?
Evobrutinib MR-T3 is developed by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (see full Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany pipeline at /company/merck-healthcare-kgaa-darmstadt-germany-an-affiliate-of-merck-kgaa-darmstadt-ger).
Is Evobrutinib MR-T3 also known as anything else?
Evobrutinib MR-T3 is also known as M2951.
What development phase is Evobrutinib MR-T3 in?
Evobrutinib MR-T3 is in Phase 1.
Related
- Manufacturer: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany — full pipeline
- Also known as: M2951
- Compare: Evobrutinib MR-T3 vs similar drugs
- Pricing: Evobrutinib MR-T3 cost, discount & access